Want to see IL:KMDA full AI Analyst Report?
KMDA Stock Chart & Stats
2533.00
-41.00(-1.90%)
At close: 4:00 PM EDT
2533.00
-41.00(-1.90%)
Day’s Range― - ―
52-Week Range1,860.97 - 2,749.59
Previous CloseN/A
Volume64.77K
Average Volume (3M)184.05K
Market Cap
₪1.53B
Enterprise Value1.09K
Total Cash (Recent Filing)₪69.66M
Total Debt (Recent Filing)₪11.72M
Price to Earnings (P/E)22.5
Beta0.66
Next Earnings
Nov 16, 2026Next Dividend Ex-DateN/A
Dividend Yield4.81%
Share Statistics
EPS (TTM)0.38
Shares Outstanding57,694,270
10 Day Avg. Volume127,879
30 Day Avg. Volume184,049
Financial Highlights & Ratios
PEG Ratio0.40
Price to Book (P/B)1.52
Price to Sales (P/S)2.09
P/FCF Ratio24.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₪4,311.45Price Target Upside70.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.49
Revenue Forecast (FY)₪203.52M
Bulls Say, Bears Say
Bulls Say
Improved Profitability And Operating PerformanceKamada is demonstrating stronger operating performance, with double-digit first-half revenue, EBITDA, and net income growth. The 26% adjusted EBITDA margin indicates meaningful earnings quality, while reiterated growth targets support the potential for continued profitability over the next several quarters.
Conservative Balance SheetVery low leverage gives Kamada substantial financial flexibility and reduces refinancing exposure as it invests in plasma capabilities and commercial expansion. A stronger equity base and improved returns also indicate better capital efficiency, helping the company fund operations and strategic initiatives with less balance-sheet strain.
Strategic Plasma Supply AgreementThe multiyear plasma agreement provides visible contracted demand and validates investments in U.S. plasma collection. It should support revenue visibility and utilization of the company’s vertically integrated capabilities, while creating a foundation for further commercial scale in plasma-derived products.
Bears Say
Gross Margin And Product-mix PressureChanging product and market mix can make profitability less predictable even when revenue grows, particularly across plasma-derived products and services with different economics. The reported gross-profit decline suggests that recent EBITDA strength may not translate into steadily expanding margins without improved mix or operating leverage.
CFO Departure Creates Execution RiskThe departure of a long-serving CFO introduces transition risk during a period of commercial expansion, plasma investment, and growing operational complexity. Although a search and transition plan are underway, changes in financial leadership could temporarily affect reporting continuity, controls, and capital allocation execution.
Uneven Cash-flow ConversionRecent cash generation has improved, but the uneven historical record shows that accounting earnings do not always convert consistently into free cash flow. This can constrain internally funded investment during weaker periods and makes the durability of cash generation less certain than the latest improvement alone suggests.
Kamada News
KMDA FAQ
What was Kamada’s price range in the past 12 months?
Kamada lowest stock price was 1860.97 and its highest was 2749.59 in the past 12 months.
What is Kamada’s market cap?
Kamada’s market cap is ₪1.53B.
When is Kamada’s upcoming earnings report date?
Kamada’s upcoming earnings report date is Nov 16, 2026 which is in 47 days.
How were Kamada’s earnings last quarter?
Kamada released its earnings results on Aug 12, 2026. The company reported 52.413 earnings per share for the quarter, beating the consensus estimate of 34.129 by 18.283.
Is Kamada overvalued?
According to Wall Street analysts Kamada’s price is currently Undervalued.
Does Kamada pay dividends?
Kamada pays a Semiannually dividend of 50.648 which represents an annual dividend yield of 4.81%. See more information on Kamada dividends here
What is Kamada’s EPS estimate?
Kamada’s EPS estimate is 39.
How many shares outstanding does Kamada have?
Kamada has 57,694,270 shares outstanding.
What happened to Kamada’s price movement after its last earnings report?
Kamada reported an EPS of 52.413 in its last earnings report, beating expectations of 34.129. Following the earnings report the stock price went down -3.146%.
Which hedge fund is a major shareholder of Kamada?
Currently, no hedge funds are holding shares in IL:KMDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kamada Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
₪4,311.45 (70.21% Upside)
₪4,311.45 (70.21% Upside)
Blogger Sentiment
Bullish
IL:KMDA Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.70%
12-Months-Change
Fundamentals
Return on Equity
4.81%
Trailing 12-Months
Asset Growth
2.11%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kamada
Kamada Ltd. is a biopharmaceutical firm specializing in protein therapies derived from blood plasma. Its operations are divided into two primary areas: developing and marketing its own proprietary products, and distributing a portfolio of third-party pharmaceuticals. Under its proprietary segment, Kamada develops and sells treatments such as KAMRAB/KEDRAB for rabies prevention, CYTOGAM for preventing cytomegalovirus in transplant recipients (including kidney, lung, liver, pancreas, heart, and heart/lung), WINRHO SDF for immune thrombocytopenic purpura (ITP) and to prevent Rh sensitization, HEPAGAM B for post-exposure prophylaxis and to stop hepatitis B recurrence after liver transplants, VARIZIG for post-exposure varicella prophylaxis, and GLASSIA, an intravenous therapy for Alpha-1 Antitrypsin Deficiency (AATD). Additional proprietary offerings include KamRho (D) IM for preventing hemolytic disease in newborns, KamRho (D) IV for immune thrombocytopenic purpura, and an antiserum specifically designed to treat snake bites from Vipera palaestinae and Echis coloratus. Through its distribution arm, Kamada provides a diverse portfolio of pharmaceuticals and medical devices. This includes BRAMITOB for chronic pulmonary infections, FOSTER for asthma management, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, the AEROBIKA OPEP device, RUPAFIN for allergic rhinitis and urticaria, IVIG for various immunodeficiency conditions, VARITECT for chickenpox and herpes zoster, ZUTECTRA and HEPATECT CP for hepatitis B, MEGALOTECT CP for cytomegalovirus, RUCONEST for angioedema attacks, heparin sodium injection for treating and preventing thromboembolic disorders, ALBUMIN for blood plasma, Factor VIII for hemophilia A, and Factor IX for hemophilia B. The distributed range also features IXIARO for Japanese encephalitis, VIVOTIF for Salmonella Typhi, PROCYSBI for nephropathic cystinosis, LAMZEDE for alpha-mannosidosis, and ELIGARD for prostate cancer. Kamada employs a multi-channel commercial strategy, utilizing strategic partners to market its products within the United States and relying on a network of distributors for its international sales. Key strategic alliances include collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, the company's headquarters are located in Rehovot, Israel.
KMDA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive: management reported record revenues, strong adjusted EBITDA and margins, sizable operating cash flow improvement, and secured a meaningful $50M plasma supply agreement while expanding distribution and biosimilar initiatives. Notable risks and concerns include a quarter-to-quarter gross profit shift due to product mix, a planned CFO departure, modest decline in cash after a dividend, and management's decision not to raise guidance despite strong H1 results. Overall, the positive financial momentum and strategic commercial wins outweigh the limited operational and corporate governance headwinds.View all IL:KMDA earnings summariesKMDA Stock 12 Month Forecast
Average Price Target
4,311.45
▲(70.21% Upside)